Group 1 - The core point of the article is that JPMorgan has increased its stake in Guangzhou Pharmaceutical Holdings (00874) by purchasing 360,600 shares at a price of HKD 18.8482 per share, totaling approximately HKD 6.7967 million [1] - After the purchase, JPMorgan's total shareholding in Guangzhou Pharmaceutical is approximately 20.0603 million shares, representing a holding percentage of 9.12% [1]

清晨，广东茂名高州市根子镇柏桥村荔枝林里，荔枝种植大户何建和正忙碌着，荔枝树已隐隐冒出白色 花芽。"现在是荔枝抽穗期，要及时管护，农户们都开始忙起来了。"何建和自豪地说，他的合作社联合 了36户社员，管理周边2000多亩荔枝林，去年销售额超1000万元。 乡村片区组团发展，是茂名推进"百县千镇万村高质量发展工程"（下称"百千万工程"）的一个缩影。茂 名以柏桥村为节点，联动周边根子、分界、泗水3个荔枝龙眼主产镇，连线成片打造1.5万亩共富片区。 2025年，柏桥村集体经济收入预计达500万元，较2022年增长180%，辐射带动周边13个行政村集体经济 收入平均超70万元，根子镇、分界镇均入选国家级农业产业强镇、全国文明镇。柏桥片区初步形成"百 业共富、家家共富、片区共富、物质精神共富"协同共富新路径。 全链升级做成荔枝大产业 荔枝是柏桥片区特色"土特产"，如何避免"丰产不丰收"？2024年以来，茂名实施"荔枝之乡"提升行动， 进一步提升技术，把"小特产"做成富民兴村的"大产业"。 目前，茂名布局了300多个田头"智慧小站"，让荔枝24小时"鲜达"全国。同时，研发出可"锁鲜"18个月 的"冻眠"荔枝技术，为荔枝深 ...

2月2日，A股上市药企白云山（证券代码：600332）发布公告显示，公司参与合作设立的广州广药广开创业投资基金合伙企业（有限合伙）（"广药广开基 金"）已于今年1月完成工商登记、取得营业执照，并在中国证券投资基金业协会完成备案手续。公告同时披露，广药广开基金首期实缴出资合计1.2亿元。 广药广开基金出资方及出资比例为广开基金占50%、广药二期基金占48.75%、广药资本占1.25%。其中，出资占比最多的广开基金为黄埔投资控股（广州） 有限公司和广州金控基金管理有限公司的合资公司。 白云山公告显示，近日该公司接到广药资本的通知，广药广开基金已于2026年1月30日在中国证券投资基金业协会完成备案手续，并取得了《私募投资基金 备案证明》。 根据备案信息，该基金名称为广州广药广开创业投资基金合伙企业（有限合伙），管理人名称为广州广药资本私募基金管理有限公司，托管人名称为招商银 行股份有限公司。 白云山在此次公告中表示，本次投资符合广药二期基金的投资方向，有利于扩大广药二期基金投资规模、分散投资风险及加快投资步伐、提高投资效率，将 加强白云山在创新药、现代中药、高端医疗器械等生物医药前沿领域的布局，通过"投早、投小、 ...

Core Viewpoint - The company Baiyunshan has established a new venture capital fund, Guangzhou Guangyao Guangkai Venture Capital Fund, with a total initial capital contribution of 120 million yuan, aimed at enhancing its investment in innovative pharmaceuticals and medical devices [2][5]. Group 1: Fund Establishment and Registration - Baiyunshan announced the completion of the business registration and acquisition of a business license for the Guangzhou Guangyao Guangkai Venture Capital Fund in January 2026 [2][5]. - The fund has been registered with the Asset Management Association of China and has obtained the Private Investment Fund Registration Certificate [5]. Group 2: Investment Details - The total initial capital contribution for the fund is 120 million yuan, with Baiyunshan's subsidiary contributing 9.75 million yuan [3][6]. - The fund's capital structure includes 50% from Guangkai Fund, 48.75% from Guangyao Phase II Fund, and 1.25% from Guangyao Capital [5]. Group 3: Strategic Implications - The investment aligns with the strategic direction of Guangyao Phase II Fund, aiming to expand investment scale, diversify risks, and accelerate investment pace [5]. - Baiyunshan intends to strengthen its position in cutting-edge biomedicine fields through early-stage investments in promising companies, facilitating technological upgrades and extending its value chain [5]. Group 4: Overall Investment Situation - Baiyunshan's total investment in various private equity funds has reached 587 million yuan, with the largest investment being 390 million yuan in the Guangzhou Guangyao Chuantou Venture Capital Fund [6].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00874 | 說明 | 香港聯交所上市 H 股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | | 2. 股份 ...

Core Insights - The New Year shopping festival serves as a critical marketing node for brands to capture consumer demand and gain a competitive edge for the year ahead [1] - Kuaishou's Magnetic Engine provides a comprehensive operational solution for merchants, focusing on traffic strategies, tool empowerment, and policy support to meet diverse industry needs [1] Group 1: AI Tools and Smart Investment - AI tools and precise investment strategies are essential for merchants to reduce costs and enhance efficiency during digital marketing [1] - The brand Yalu Fangge optimized its content strategy and utilized AI tools to significantly increase promotional spending by 92% during the New Year festival, achieving a 129% increase in daily average spending compared to December [1] - Baiyunshan leveraged AI tools and health-focused materials to enhance operational efficiency, resulting in a 30% increase in advertising spending during the early bird period and a 200,000 increase in material exposure [1] Group 2: C Subsidy Policies and Comprehensive Collaboration - Kuaishou's C subsidy policy aims to lower operational costs for merchants and stimulate consumer potential, helping them break through competitive bottlenecks [1][2] - The brand Deyou utilized a 16% C subsidy and a multi-matrix approach to improve its live streaming engagement by 22% and enhance its infrastructure by 50%, leading to a 9% increase in ROI [2] Group 3: Fine-tuned Operations and Long-term Brand Growth - Fine-tuned operations are crucial for merchants to build brand assets and explore new growth opportunities amid concentrated consumer demand [3] - The brand Fuyan Jie optimized its promotional strategies and enhanced user purchase intent, achieving a 200% increase in spending and a 161% increase in product CTR during the New Year festival [3] - The brand Qingquan Runjia shifted its operational strategy to a product and brand combination model, resulting in a 108% increase in ROI during the festival [4] Group 4: Market Adaptation and Product Strategy - The brand Meierya focused on expanding its product line during the New Year festival, utilizing a price-cutting strategy and various promotional methods to drive sales [5] - The overall operational ecosystem of Kuaishou supports brands, factories, and newcomers in finding suitable growth paths, emphasizing the platform's capability to adapt to market demands [6]

证券代码：600332 证券简称：白云山 公告编号：2026－003 企业名称：广州白云山明兴制药有限公司 广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 子公司广州白云山明兴制药有限公司（以下简称"明兴药业"）收 到广东省药品监督管理局核准签发的《药品生产许可证》，同意明 兴药业变更生产车间名称及核减生产范围、生产车间、生产线。现将 相关情况公告如下： 一、《药品生产许可证》基本情况 许可证编号：粤 20160012 分类码：AhzxBzDhz 注册地址：广州市海珠区工业大道北 48 号 发证机关：广东省药品监督管理局 有效期至：2030 年 10 月 8 日 生产地址和生产范围： 1 钠、氯膦酸二钠、硝酸甘油溶液、盐酸乙胺丁醇、烟酸），中药前处 理及提取车间（口服制剂）；4、广州市白云区健旭三路 99 号，硬胶 囊剂，颗粒剂，小容量注射剂（含非最终灭菌），冻干粉针剂，原料 药（人工牛黄），冻干 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 第 1 頁 共 10 頁 v 1.2.0 FF301 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00874 | 說明 | 香港聯交所上市 H 股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 RMB | | | 1 RM ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 中國廣州，2026年2月3日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2026－003 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司藥品生產許可證變更的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公 ...

Core Viewpoint - The Guangzhou Pharmaceutical Group is entering a new phase of brand development with the establishment of the Brand Strategy Committee, focusing on a comprehensive brand strategy for the next five years [1]. Group 1: Brand Strategy and Management - The brand strategy framework is centered around "1+6," where "1" represents a unified brand strategy plan and "6" signifies six key strategic initiatives [1]. - The establishment of the Brand Strategy Committee marks a significant step in the company's brand construction efforts [1]. Group 2: Business Performance and Growth - The company aims to double its business performance, with key strategies including regional expansion and internationalization of technology innovation [4]. - The acquisition of Caishantang is highlighted as a successful case of regional expansion, achieving a fourfold revenue increase after expanding its market presence beyond Fujian Province [4]. Group 3: Scientific Research and Internationalization - The company emphasizes the importance of scientific research to validate the effectiveness of traditional Chinese medicine, aiming for international collaboration with research institutions in North America and Europe [5][6]. - Recent achievements include the publication of a product in a top international journal and the recognition of another product in Russia, showcasing the potential for traditional medicine to be integrated into global healthcare solutions [6]. Group 4: Strategic Partnerships and Capital Operations - Under the leadership of Li Xiaojun, the company has accelerated its capital operations and formed strategic partnerships, including a collaboration with Huawei to enhance its international strategy [7]. - The company has made significant investments in innovative drugs and high-end medical devices, with plans for substantial R&D and investment in the coming years [7]. Group 5: Policy Recommendations and Industry Development - Li Xiaojun has proposed measures to support the biopharmaceutical industry, including establishing a systematic error-correction mechanism and creating a global talent network [8]. - Recommendations also include developing a collaborative response mechanism for international trademark disputes to support companies venturing abroad [8].